Articles
🇺🇸 AmericasExpert insights, opinion pieces, and in-depth analysis on pharmaceutical trends and FDA regulations.
Eli Lilly issues data sharing ultimatum to 340B hospitals
Structured plan for Eli Lilly issues data sharing ultimatum to 340B hospitals
New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights
A novel radiopharmaceutical is demonstrating promising results in patients who have previously been treated with Pluvicto, signaling a potential shift in the advanced prostate cancer treatment paradigm. This development presents significant competitive implications for companies like Abivax, Fulcrum, Convergent, and Vera.
STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
Structured plan for STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
ASCO 2026 Preview: Key Data and Trends in Cancer Research
This ASCO preview highlights crucial developments in cancer research, focusing on key data presentations and emerging trends that will shape the oncology landscape. Investors and BD teams should monitor these advancements for strategic insights.
Pancreatic Cancer Drug Shows Phase 3 Survival Gain
Structured plan for Experimental pancreatic cancer drug offers new hope in major trial
Camizestrant Delay and Bria-IMT Breast Cancer Week
Structured plan for This Week in Breast Cancer: Camizestrant Delay, Bria-IMT Data, Recurrence Test
Vyome Q1 2026: FDA Filings and Cash Strength
Vyome Holdings announced its first quarter 2026 financial results, underscoring significant progress with key FDA filings and a strengthened balance sheet. The company's performance indicates a strategic focus on regulatory advancement and financial stability.
Rallybio Avenzo Oncology Reverse Merger $215M
Structured plan for Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing
Sun Pharma to Buy Organon for $14.00 Cash
Structured plan for Organon (OGN) to be Acquired by Sun Pharma for $14.00 Cash per Share
Top 10 U.S. Biopharma Clusters 2026
Structured plan for Top 10 U.S. Biopharma Clusters 2026
Duchesnay Pharma Growth Five Years After Buyout
Five years after its acquisition by senior management in 2021, Duchesnay Pharmaceutical Group (DPG) has achieved significant and sustained growth across sales, exports, and employment. This expansion solidifies DPG's standing as one of Canada's few comprehensive pharmaceutical businesses.
Inventiva Capital Structure: Debt and Equity Mix
Inventiva has announced a significant optimization of its capital structure, incorporating both debt and equity financing. This strategic move is designed to bolster the company's financial position ahead of anticipated Phase 3 clinical trial readouts.
FDA Clears Iovance IOV-5001 IL-12 TIL Trial
The FDA has cleared Iovance Biotherapeutics' Investigational New Drug application for IOV-5001, a novel IL-12 tethered TIL therapy designed for advanced solid tumors. This clearance allows for the initiation of a Phase 1/2 clinical trial, potentially expanding treatment options for patients with difficult-to-treat indications.
Abivax Stock Plummets Amid Safety Concerns in Ulcerative Colitis Trial
Abivax's stock experienced a significant decline of over 37% after releasing new trial data for its ulcerative colitis drug, obefazimod. While the drug demonstrated strong efficacy, the emergence of cancer cases in trial participants has cast a shadow over its prospects.
FDA Approves Ensitrelvir for COVID-19 PEP
Structured plan for FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
Structured plan for AbiVax falls as safety worries cloud ‘landmark’ immune drug results
FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
Structured plan for FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment
Personalized mRNA cancer vaccines are emerging as a powerful new weapon against melanoma, leveraging individual patient tumor data to create tailored treatments. This innovative approach, building on the success of mRNA technology, shows significant promise in preventing cancer recurrence and offers new hope for patients.
Healthcare AI Market Concentration: Lifecycle Regulation as an Entry Barrier
Lifecycle regulation for AI in healthcare is evolving beyond initial algorithm approval, creating significant entry barriers and leading to market concentration. This shift impacts how new AI solutions are developed, validated, and commercialized.
FDA Overhauls Human Factors Guidance: New Submission Category Introduced
The FDA has updated its human factors guidance, introducing new risk-based submission categories and expanding examples for modified devices. This revision aims to provide clearer frameworks for manufacturers regarding the human factors information required in premarket submissions.